🇺🇸 FDA
Pipeline program

Rifaximin

2017-ZSLY-06

Phase 3 small_molecule active

Quick answer

Rifaximin for Crohn Disease is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Crohn Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials